A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx, Umbilical Cord Blood (UCB) Stem and Progenitor Cells Expanded Ex Vivo, in Subjects with Hematologic Malignancies following Myeloablative Therapy

Trial Profile

A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx, Umbilical Cord Blood (UCB) Stem and Progenitor Cells Expanded Ex Vivo, in Subjects with Hematologic Malignancies following Myeloablative Therapy

Completed
Phase of Trial: Phase II/III

Latest Information Update: 27 Jul 2015

At a glance

  • Drugs Carlecortemcel-L (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ExCELL
  • Sponsors Teva Pharmaceutical Industries - Gamida-Cell (JV)
  • Most Recent Events

    • 09 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jul 2013 Based on interim results from this trial, the FDA has recommended that an additional phase III trial be conducted for registration, according to a Gamida Cell media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top